TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE-NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE-NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called ESG401 against standard chemotherapy as a first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. About 504 participants will be randomly assigned to receive either ESG401 or a chemotherapy chose…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:52 UTC
-
New drug GTAEXS617 enters human trials for tough cancers
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug that seeks out a protein called Nectin-4 on cancer cells. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The main goals are to find a saf…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New drug XB010 shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New hope for hard-to-treat breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults with inoperable or metastatic disease will receive either AK11…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 16, 2026 23:49 UTC
-
New hope for Hard-to-Treat breast cancer: experimental drug MR001 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MR001 in people with advanced triple-negative breast cancer (TNBC) that has worsened after previous treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. About 42 participants will recei…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New drug PQ203 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests the safety and best dose of a new drug called PQ203 in people with advanced solid tumors, including triple-negative breast cancer. About 80 participants whose cancer has progressed after standard treatments will receive the drug. The goal is to find a…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New IgE antibody trial targets Hard-to-Treat ovarian and breast cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have high levels of a protein called folate receptor alpha. The study has two parts: first, finding a safe dose, and then checki…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Epsilogen Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy aims to boost breast cancer treatment success
Disease control Recruiting nowThis study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 40 participants will receive on…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Blood test catches hidden breast cancer before scans can see it
Disease control Recruiting nowThis study is for people with a high-risk type of breast cancer (triple negative) who still have cancer after standard treatment and surgery. Researchers will use a simple blood test to look for tiny bits of cancer DNA that might be left in the body. If the blood test finds cance…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy aims to halt advanced breast cancer
Disease control Recruiting nowThis study is for people with advanced triple-negative breast cancer that cannot be removed by surgery. It tests different ways of combining radiation therapy with immunotherapy to see which pattern works best to stop the cancer from growing. About 60 participants will take part,…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New pill hopes to unleash immune system against tough cancers
Disease control Recruiting nowThis early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new oral drug, NKT5097, in 205 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. The study focuses on breast cancer and other tumors with specific g…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
Can a second dose of powerful cancer drugs work again?
Disease control Recruiting nowThis study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Can adding radiation before surgery boost immune response in aggressive breast cancer?
Disease control Recruiting nowThis study is for people with operable, lymph node-positive triple negative breast cancer. It tests whether giving a low or high dose of radiation to the breast tumor along with immunotherapy (pembrolizumab) before standard chemotherapy can improve the chance of eliminating all c…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Engineered immune cells take on Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target specific markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have not responded to standard therapies. The goal is to se…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New hope for Hard-to-Treat breast cancer: drug trial opens
Disease control Recruiting nowThis study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer (TNBC) who have already tried 1 to 3 other treatments. The goal is to see if the drug can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also m…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New radiation therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new treatment that delivers radiation directly to cancer cells in people with advanced solid tumors that cannot be removed by surgery. The treatment uses a special molecule to find and attach to cancer cells, then delivers a radioactive payload to destroy …
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug NRM-823 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New combo aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug QL1706 to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 30 patients with stage II or III disease. Participants receive 8 cycles of treatment over about 6 months, followed by surgery. The mai…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New drug EXS74539 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
New hope for advanced cancers? early trial of JAB-2485 begins
Disease control Recruiting nowThis study tests a new drug called JAB-2485 in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The trial is in early …
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Gut bugs join fight: probiotic boosts breast cancer chemo?
Disease control Recruiting nowThis study tests whether adding a probiotic supplement called Biolosion to standard chemotherapy before surgery can help more people with early-stage triple-negative breast cancer achieve a complete remission. About 192 women will be randomly assigned to receive either standard t…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New study gathers key materials for Next-Gen cancer therapy
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC